Dabrafenib for treatment of BRAF-mutant melanoma

References

• American Cancer SocietyCancer Facts and Figures 2013Atlanta, GAAmerican Cancer Society2013
   Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/csr/1975_2009_pops09/Accessed October 9, 2013
   Google Scholar
• BalchCMGershenwaldJESoongS-JFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol200927366199620619917835
   PubMed Web of Science ®Google Scholar
• SerroneLZeuliMSegaFMCognettiFDacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overviewJ Exp Clin Cancer Res2000191213410840932
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMGp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• GuirguisLMYangJCWhiteDESafety and efficacy of high-dose interleukin-2 therapy in patients with brain metastasesJ Immunother2002251828711924913
   PubMed Web of Science ®Google Scholar
• AgarwalaSSKirkwoodJMGoreMTemozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II studyJ Clin Oncol200422112101210715169796
   PubMed Web of Science ®Google Scholar
• SeiglerHFLucasVSPickettNJHuangATDTIC, CCNU, bleomycin, and vincristine in metastatic melanomaCancer19804611234623486159960
   PubMed Web of Science ®Google Scholar
• PuntCJAvan HerpenCMLJansenRLHVreugdenhilGMullerEWde MulderPHChemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon α for metastatic melanoma: a multicentre phase II studyBr J Cancer19977622662699231931
   PubMed Web of Science ®Google Scholar
• AtkinsMBHsuJLeeSPhase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200826355748575419001327
   PubMed Web of Science ®Google Scholar
• EtonOLeghaSSBedikianAYSequential biochemotherapy for metastatic melanoma: results from a Phase III randomized trialJ Clin Oncol20022082045205211956264
   PubMed Web of Science ®Google Scholar
• ShinozakiMFujimotoAMortonDLHoonDSIncidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomasClin Cancer Res20041051753175715014028
   PubMed Web of Science ®Google Scholar
• HodisEWatsonIRKryukovGVA landscape of driver mutations in melanomaCell2012150225126322817889
   PubMed Web of Science ®Google Scholar
• GoelVKLazarAJFWarnekeCLRedstonMSHaluskaFGExamination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanomaJ Invest Dermatol2006126115416016417231
   PubMed Web of Science ®Google Scholar
• HershEMO’DaySJPowderlyJA Phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaInvest New Drugs200129348949820082117
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of the singleagent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudDSafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• SegerRKrebsEGThe MAPK signaling cascadeFASEB J1995997267357601337
   PubMed Web of Science ®Google Scholar
• DhillonASHaganSRathOKolchWMAP kinase signaling pathways in cancerOncogene200726223279329017496922
   PubMed Web of Science ®Google Scholar
• FangJYRichardsonBCThe MAPK signaling pathways and colorectal cancerLancet Oncol20056532232715863380
   PubMed Web of Science ®Google Scholar
• KaladyMFDejuliusKLSanchezJABRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosisDis Colon Rectum201255212813322228154
   PubMed Web of Science ®Google Scholar
• FrascaFNuceraCPellegritiGBRAF (V600E) mutation and the biology of papillary thyroid cancerEndocr Relat Cancer200815219120518310287
   PubMed Web of Science ®Google Scholar
• LongGVMenziesAMNagrialAMPrognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol201129101239124621343559
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• WanPTGarnettMJRoeSMMechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFCell2004116685586715035987
   PubMed Web of Science ®Google Scholar
• TsaiJLeeJTWangWDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A200810583041304618287029
   PubMed Web of Science ®Google Scholar
• LeeJTLiLBraffordPAPLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomasPigment Cell Melanoma Res201023682082720973932
   PubMed Web of Science ®Google Scholar
• LaquerreSArnoneMMossKA selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutationMol Cancer Ther200912Suppl 1 Abstr B88
   Google Scholar
• FalchookGSLongGVKurzrockRDabrafenib in patients with melanoma, untreated brain metastaese, and other solid tumours: a phase 1 dose-escalation trialLancet201237998291893190122608338
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJDimidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJDimidovLVAn update on BREAK-3, a Phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)Poster 9013 presented at the 49th annual meeting of the American Society of Clinical OncologyChicago, ILMay 31 to June 4, 2013
   Google Scholar
• LongGVTrefzerUDaviesMADabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialLancet2012131110871095
   Web of Science ®Google Scholar
• SolitDBRosenNResistance to BRAF inhibition in melanomasN Engl J Med2011364877277421345109
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulationNature2010468732697397721107323
   PubMed Web of Science ®Google Scholar
• VillanuevaJVulturALeeJTAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KCancer Cell201018668369521156289
   PubMed Web of Science ®Google Scholar
• GregerJGEastmanSDZhangVCombinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsMol Cancer Ther201211490992022389471
   PubMed Web of Science ®Google Scholar
• JohnnessenCMBoehmJSKimSYCOT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivationNature2010468732696897221107320
   PubMed Web of Science ®Google Scholar
• DumazNHaywardRMartinJIn melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingCancer Res200666199483949117018604
   PubMed Web of Science ®Google Scholar
• PoulikakosPIPersaudYJanakirmanMRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature2011480737738739022113612
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• JankuFLeeJJTsimberidouAMPIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersPLoS One201167e2276921829508
   PubMed Web of Science ®Google Scholar
• YuanTLCantleyLCPI3K pathway alterations in cancer: Variations on a themeOncogene200827415497551018794884
   PubMed Web of Science ®Google Scholar
• MendozaMCErEEBlenisJThe RAS-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends Biochem Sci201136632032821531565
   PubMed Web of Science ®Google Scholar
• Sanchez-HernandezIBaqueroPCallerosLChiloechesADual inhibition of (V600E) BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanismCancer Lett2012314224425522056813
   PubMed Web of Science ®Google Scholar
• SumimotoHImabayashiFIwataTKawakamiYThe BRAF-MAPK signaling pathway is essential for cancer – immune evasion in human melanoma cellsJ Exp Med200620371651165616801397
   PubMed Web of Science ®Google Scholar
• HongDSVenceLFalchookGSBRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competencyClin Cancer Res20121882326371522355009
   PubMed Web of Science ®Google Scholar
• WeichselRDixCWoolridgeLProfound inhibition of antigen-specific T-cell effector functions by dasatinibClin Cancer Res20081482484249118413841
   PubMed Web of Science ®Google Scholar
• ZhaoWGuYHSongRQuBQXuQSorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylationLeukemia20082261226123318337760
   PubMed Web of Science ®Google Scholar
• WilmottJSLongGVHowieJRSelective BRAF inhibitors induce marked T-cell infltration into human metastatic melanomaClin Cancer Res20121851386139422156613
   PubMed Web of Science ®Google Scholar
• RibasAHodiFSCallahanMKontoCWolchokJHepatotoxicity with combination of vemurafenib and ipilimumabN Engl J Med2013368141365136623550685
   PubMed Web of Science ®Google Scholar
• StraussmanRMorikawaTSheeKTumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature2012487740850050422763439
   PubMed Web of Science ®Google Scholar
• WilsonTRFridlyandJYanYWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature2012487740850550922763448
   PubMed Web of Science ®Google Scholar
• PuriNAhmedSJanamanchiVc-Met is a potentially new therapeutic target for treatment of human melanomaClin Cancer Res20071372246225317404109
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationDabrafenib Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm354477.htmAccessed October 9, 2013
   Google Scholar
• National Institutes of HealthDabrafenib Available from: http://www.clinicaltrials.gov/ct2/results?term=dabrafenib&search=searchAccessed November 7, 2013
   Google Scholar
• GirottiMRMaraisRDéjà vu: EGF receptors drive resistance to BRAF inhibitorsCancer Discov20133548749023658295
   PubMed Web of Science ®Google Scholar